Brittany Barreto has expanded her DNA dating technology to a compatibility company named We Have Chemistry. Courtesy of WeHaveChemistry

As Brittany Barreto was developing and promoting her DNA-based dating app, Pheramor, that can establish compatibility in prospective couples using a certain string of genetics, she made some couples very jealous. While not single, they wanted to know the compatibility they have with their partner.

"For every single we connected with through Pheramor, there were at least three couples that wanted to complete the DNA swab to find out their compatibility," she says in a news release.

Now, Barreto and her team, which now includes acclaimed relationship expert Laura Berman, have developed WeHaveChemistry, a series of tests and DNA analysis that can give couples a look at their compatibility. And, WeHaveChemistry has taken it a step further to include more than just DNA in the report.

"The team is very excited about WeHaveChemistry," says Barreto in the release. "We've done our research and carefully crafted two reports: the socioemotional analysis and the DNA report. All couples will receive both reports to analyze their physical and emotional chemistry—which we refer to as their 'Love Alchemy."

The results aren't categorized as good or bad, and there's no score determined for couples — the findings are meant to be used to enhance the relationship and as a guide for navigating the trials and tribulations that often come with monogamy.

"The most important way for couples to ensure that their relationship stays strong is to both play to their strengths and to be honest and curious about their areas for growth," says Berman in the release. "We all have areas where we need to stretch a little, both as partners and as people, and couples can apply the findings of the SEA to their relationships and begin growing right away. In addition, the SEA identifies where we are strongest, what we should celebrate and honor, and the areas which we can rely on as a firm foundation when times get tough."

The process goes as follows:

  • Couples complete the DNA kit.
  • Each person takes the socioemotional analysis quiz, which analyzes emotional intimacy, physical connection, purpose, and future vision. The quiz will identify the person's strengths.
  • Each person receive their DNA report, which assesses sexual chemistry based on genetics.
  • The two aspects — the DNA report and the quiz results — are combined to predict and guide chemistry.

The way genetics affects attraction is completely subconscious and instinctual, dating back to primitive times.

"The science behind attraction based on your DNA is that people are attracted to one another when their immune systems are different — opposites attract is biologically true," Barreto says in a previous InnovationMap article. "When we were cavewomen and cavemen, we didn't know who was our uncle and who was our cousin, so we used our nose to figure out who is genetically diverse compared to us. If you're genetically diverse, then you're probably not my relative, and therefore we'd have healthier children."

Of course, nowadays, there are many more factors that go into compatibility and both Pheramor and WeHaveChemistry have included that in their assessments.

Swabbing for love

Courtesy of WeHaveChemistry

The DNA kit has swabs and information for two people and is sent through the mail.




Brittany Barreto wants to expand her DNA dating technology to a B-to-B model and compatibility test — all under a new company called X&Y Technologies. Karla Martin/Pheramor

Houston DNA-based dating app expands brand and plans new ways to use its technology

Love as a science

For over two years, Brittany Barreto has been playing matchmaker with her DNA-based dating app, Pheramor, but now she's ready to take it to the next level.

Pheramor, which sequences users' DNA and datamines their social media activity to determine compatibility, is transforming into becoming a product of a newly formed company called X&Y Technologies. The company, Barreto says, will have multiple products, all relating to using that same DNA technology Pheramor has perfected.

Among the first three products X&Y is working to create is a B-to-B software-as-a-service company, where established dating companies can employ Pheramor's technology for its existing app and customers. Barreto says she has two letters of intent for the B-to-B model, one of which is a dating app with 160,000 users.

Barreto unveiled the new company at The Cannon's female entrepreneur pitch night on January 24, but expanding her technology's reach has been on her mind for a while. She cited major dating companies that have their eyes on DNA dating, but haven't yet figured out the infrastructure. That, she says, is where X&Y's SaaS model comes in.

"Our traction with the dating app was a fantastic way to prove that we are the thought leaders, we have the infrastructure, and we have the algorithm and we've proven that the market is ready to buy a DNA kit to find love," she says in her pitch.

In addition, X&Y will have a compatibility test for couples wishing to learn of their own DNA-based compatibility. The tool, called We Have Chemistry, is getting ready to launch and already has preorders coming in.

"Pheramor's test is really the gold standard and industry leader in this test," she says, explaining how Pheramor's technology can be used by these existing dating apps.

She talked about how this is the time for DNA tests — from 23andme to Pheramor — and how it's not weird to send your spit in the mail. As Barreto says in her pitch, there's so much more potential for uses of the technology in what's called contextualized genetics.

"I know that my technology is way bigger than just this one market," Barreto says. "I believe the future of product is about combining the big data of genomics and DNA with the big data of your digital footprint. Nobody has ever combined your Facebook data with your DNA to figure out what's the best diet, exercise or work environment for you."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.